J9025 Azacitidine injection
Also known as: Vidaza, Azacitidine
Azacitidine administered by injection; a DNA methyltransferase inhibitor used for myelodysplastic syndromes and acute myeloid leukemia.
In Plain Language
Myelodysplastic syndrome treatment injection; Chemotherapy medication
Clinical Context
Used for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Inhibits DNA methylation.
RVU Information
CPT J9025 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J9025?
CPT J9025 (Azacitidine injection) is a J Codes (Drugs) code. Azacitidine administered by injection; a DNA methyltransferase inhibitor used for myelodysplastic syndromes and acute myeloid leukemia.
How is J9025 administered?
CPT J9025 is administered by a healthcare provider, typically via injection or infusion. Used for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Inhibits DNA methylation. It is used by Oncology, Hematology, Internal Medicine.
When is CPT J9025 used?
Used for myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. Inhibits DNA methylation.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.